Skip to content
value.today
Neuronetics, Inc. logo

Neuronetics, Inc.

STIM
$162 Mmarket cap on Oct 23, 2026+107.3% since Jan 2024
1M
-27.8%
Compare
World rank
#17,042
Revenue
$149 M
For year ending December-2025
Net income
$-39 M
-26.1% margin
SEC filing
Employees
—

Neuronetics, Inc. in brief

Neuronetics, Inc. is a listed company in the Diagnostics and Research industry, based in Malvern, Pennsylvania, USA. It was founded in 2003. Its market value was $162 M on 23 October 2026, which makes it the 17,042nd largest listed company in the world and the 3,274th largest in the USA on this site. In the year to December 2025 it had sales of $149 M and a net loss of $39 M. Daniel L. Reuvers is its chief executive. Its largest business segments by sales in 2025 were Clinical Services (58%) and Medical Device (42%). Its shares trade under the symbol STIM (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Neuronetics, Inc.

Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.

Neuronetics became the "first and only Food and Drug Administration (FDA) approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device (FDA approval K061053)."

They manufacture a transcranial magnetic stimulation device, NeuroStar. The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Neuronetics, Inc. timeline

5 events, 2003–2025
  1. 2003
  2. 🏁
    · approximate
    Founded
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2018
  5. •
    Legal Entity Identifier issued
    LEI 549300T0911ILTTG7P06 registered.
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 29 June 2018; shares registered for exchange trading on 19 June 2018.
  7. 2025
  8. 💰
    Record revenue of $149 million
    FY2025, the highest of the 8 years on record.

Events of Neuronetics, Inc. from Wikidata, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$68 M$136 M$203 M$271 M2020202120222023202420252026

World rank over time

▲ up 2,572 places since 2020
2020-01-01: #19642#19,64220202021-01-01: #15276#15,27620212022-01-07: #22699#22,69920222022-12-25: #19114#19,11420222023-07-30: #24608#24,60820232024-01-05: #22708#22,70820242026-03-08: #10042#10,04220262026-08-01: #14761#14,76120262026-09-24: #15920#15,92020262026-10-23: #17070#17,0702026

Rank in USA: #3,820 (Jan 2020) · #3,192 (Jan 2021) · #4,418 (Jan 2022) · #3,869 (Dec 2022) · #4,654 (Jul 2023) · #3,855 (Jan 2024) · #1,947 (Mar 2026) · #2,977 (Aug 2026) · #3,065 (Sep 2026) · #3,278 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
1.0×
Price / book
7.2×
Free cash flow yield
-13.1%
Net margin (TTM)
-14.4%
Operating margin
-21.1%
Return on equity
-103.1%
Liabilities / assets
81.5%
Net debt
$38M
Revenue growth
+99.2%
R&D / revenue
4.4%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $53M, net income $-24M$53MFY18Fiscal year ending Dec 2019: revenue $63M, net income $-29M$63MFY19Fiscal year ending Dec 2020: revenue $49M, net income $-27M$49MFY20Fiscal year ending Dec 2021: revenue $55M, net income $-31M$55MFY21Fiscal year ending Dec 2022: revenue $65M, net income $-37M$65MFY22Fiscal year ending Dec 2023: revenue $71M, net income $-30M$71MFY23Fiscal year ending Dec 2024: revenue $75M, net income $-44M$75MFY24Fiscal year ending Dec 2025: revenue $149M, net income $-39M$149MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$149M+99.2%$-31M$-39M-26.1%
Dec 2024$75M+5.0%$-35M$-44M-58.4%
Dec 2023$71M+9.4%$-31M$-30M-42.3%
Dec 2022$65M+17.9%$-35M$-37M-57.0%
Dec 2021$55M+12.3%$-28M$-31M-56.4%
Dec 2020$49M-21.4%$-22M$-27M-55.7%
Dec 2019$63M+18.7%$-27M$-29M-46.3%
Dec 2018$53M—$-20M$-24M-45.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-20M$1M$-21M$-0.59—
Dec 2024$-31M$1M$-32M$-1.38—
Dec 2023$-32M$2M$-34M$-1.05—
Dec 2022$-31M$3M$-34M$-1.38—
Dec 2021$-28M$2M$-30M$-1.22—
Dec 2020$-28M$1M$-29M$-1.46—
Dec 2019$-30M$1M$-31M$-1.58—
Dec 2018$-21M$1M$-22M$-2.69—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$160M
Net income, trailing 12 months
$-23M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $22M, net income $-13M$22MDec ’24Three months to Mar 2025: revenue $32M, net income $-13M$32MMar ’25Three months to Jun 2025: revenue $38M, net income $-10M$38MJun ’25Three months to Sep 2025: revenue $37M, net income $-9M$37MSep ’25Three months to Dec 2025 (from the annual report): revenue $42M, net income $-7M$42MDec ’25Three months to Mar 2026: revenue $34M, net income $-11M$34MMar ’26Three months to Jun 2026: revenue $42M, net income $-3M$42MJun ’26Three months to Sep 2026: revenue $42M, net income $-2M$42MSep ’26

Latest quarter to Sep 2026: revenue $42M (+12.5% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Neuronetics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$149 M
Operating income
$-31 M
Net income
$-39 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$142 M
Total liabilities
$115 M
Total equity
$22 M

As of December-2025

Top 96 institutional investors in Neuronetics, Inc.#

As of Sep 30, 2026
96 institutions held 45.0 M shares (about 57.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 43.1%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Neuronetics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Madryn Asset Management, LP18,540,4880 (0.00%)23.85%$43 MNov 12, 2026
2Point72 Asset Management, L.P.4,163,261New5.36%$10 MNov 16, 2026
3Wexford Capital LP2,002,6250 (0.00%)2.58%$5 MNov 13, 2026
4Marshall Wace, LLP1,551,840+1,066,148 (+219.51%)2.00%$4 MNov 13, 2026
5Vanguard Capital Management LLC1,527,373+20,276 (+1.35%)1.97%$4 MNov 13, 2026
6Eversept Partners, LP1,402,548New1.80%$3 MNov 16, 2026
7Lane Generational LLC1,262,179-371,193 (-22.73%)1.62%$3 MNov 9, 2026
8HighTower Advisors, LLC1,101,502+537,761 (+95.39%)1.42%$3 MNov 10, 2026
9Masters Capital Management LLC1,000,0000 (0.00%)1.29%$2 MNov 16, 2026
10FourWorld Capital Management LLC937,401-806,741 (-46.25%)1.21%$2 MNov 16, 2026
11AdvisorShares Investments LLC924,380+181,585 (+24.45%)1.19%$2 MNov 9, 2026
12Ikarian Capital, LLC810,182+109,000 (+15.55%)1.04%$2 MNov 16, 2026
13Morgan Stanley753,323+690,430 (+1097.79%)0.97%$2 MNov 13, 2026
14Citadel Advisors LLC639,774+217,871 (+51.64%)0.82%$1 MNov 16, 2026
15Driehaus Capital Management LLC580,549New0.75%$1 MNov 16, 2026
16UBS Group AG573,630-1,705,469 (-74.83%)0.74%$1 MNov 10, 2026
17Geode Capital Management, LLC480,396+21,922 (+4.78%)0.62%$1 MNov 6, 2026
18D. E. Shaw & Co., Inc.461,710New0.59%$1 MNov 16, 2026
19BlackRock, Inc.452,618-144,004 (-24.14%)0.58%$1 MNov 13, 2026
20Squarepoint Ops LLC435,951+341,335 (+360.76%)0.56%$1 MNov 9, 2026
21Renaissance Technologies LLC424,400New0.55%$1 MNov 12, 2026
22Millennium Management LLC342,434+142,984 (+71.69%)0.44%$1 MNov 16, 2026
23Diametric Capital, LP323,452New0.42%$1 MNov 16, 2026
24State Street Corp302,699+12,400 (+4.27%)0.39%$1 MNov 12, 2026
25Boothbay Fund Management, LLC281,367+92,104 (+48.66%)0.36%$1 MNov 16, 2026
Show all 96: investors 26 to 96
Institutional investors 26 to 96 in Neuronetics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Balyasny Asset Management L.P.255,020New0.33%$1 MNov 16, 2026
27Goldman Sachs Group Inc253,004-11,084 (-4.20%)0.33%$1 MNov 16, 2026
28HRT Financial LP251,721+163,011 (+183.76%)0.32%$1 MNov 13, 2026
29Jane Street Group, LLC239,475+54,225 (+29.27%)0.31%$1 MNov 12, 2026
30Vanguard Fiduciary Trust Co239,190-25,544 (-9.65%)0.31%$1 MNov 13, 2026
31Quadrature Capital Ltd214,351+183,495 (+594.68%)0.28%$1 MNov 13, 2026
32BRC Group Holdings, Inc.200,000New0.26%$0 MNov 13, 2026
33Bank of New York Mellon Corp176,317New0.23%$0 MNov 5, 2026
34XTX Topco Ltd108,274-112,049 (-50.86%)0.14%$0 MNov 16, 2026
35Bank Of America Corp /de/102,753+34,558 (+50.68%)0.13%$0 MNov 16, 2026
36ADAR1 Capital Management, LLC100,0000 (0.00%)0.13%$0 MNov 16, 2026
37Northern Trust Corp93,902+4,764 (+5.34%)0.12%$0 MNov 16, 2026
38Bridgeway Capital Management, LLC90,305-4,900 (-5.15%)0.12%$0 MNov 16, 2026
39Empowered Funds, LLC90,305New0.12%$0 MNov 13, 2026
40Susquehanna International Group, LLP87,632-98,121 (-52.82%)0.11%$0 MNov 16, 2026
41Canada Pension Plan Investment Board80,500New0.10%$0 MNov 16, 2026
42GAMCO Investors, Inc. Et Al79,2000 (0.00%)0.10%$0 MNov 12, 2026
43Jefferies Financial Group Inc.75,000New0.10%$0 MNov 5, 2026
44Dauntless Investment Group, LLC69,228-299,959 (-81.25%)0.09%$0 MNov 16, 2026
45Centiva Capital, LP63,184-222,729 (-77.90%)0.08%$0 MNov 13, 2026
46VestGen Advisors, LLC50,200-79 (-0.16%)0.06%$0 MOct 27, 2026
47Cruiser Capital Advisors, LLC48,9000 (0.00%)0.06%$0 MNov 16, 2026
48Tudor Investment Corp Et Al48,343-76,518 (-61.28%)0.06%$0 MNov 16, 2026
49Allworth Financial LP45,756+45,587 (+26974.56%)0.06%$0 MNov 17, 2026
50Invesco Ltd.42,228-26,112 (-38.21%)0.05%$0 MNov 12, 2026
51Arax Advisory Partners39,417-426 (-1.07%)0.05%$0 MNov 12, 2026
52T3 Companies, LLC37,600New0.05%$0 MOct 22, 2026
53Virtu Financial LLC37,289+7,707 (+26.05%)0.05%$0 MNov 17, 2026
54Engineers Gate Manager LP35,953-21,222 (-37.12%)0.05%$0 MNov 16, 2026
55JBF Capital, Inc.33,166-200,000 (-85.78%)0.04%$0 MNov 16, 2026
56Two Sigma Securities, LLC30,004New0.04%$0 MNov 16, 2026
57Jump Financial, LLC29,389New0.04%$0 MNov 13, 2026
58Prelude Capital Management, LLC27,775New0.04%$0 MNov 16, 2026
59Barclays PLC25,904+20,065 (+343.64%)0.03%$0 MNov 6, 2026
60Caitong International Asset Management Co., Ltd24,495-16,825 (-40.72%)0.03%$0 MOct 29, 2026
61Price T Rowe Associates Inc /MD/24,2460 (0.00%)0.03%$0 MNov 16, 2026
62Schonfeld Strategic Advisors LLC23,995New0.03%$0 MNov 16, 2026
63Fielder Capital Group LLC22,822-81 (-0.35%)0.03%$0 MNov 12, 2026
64Axq Capital, LP21,942+10,918 (+99.04%)0.03%$0 MNov 12, 2026
65State of Wyoming21,342-2,140 (-9.11%)0.03%$0 MOct 28, 2026
66AQR Capital Management LLC20,637-97,185 (-82.48%)0.03%$0 MNov 16, 2026
67Composition Wealth, LLC19,8510 (0.00%)0.03%$0 MNov 10, 2026
68Tower Research Capital LLC (TRC)19,805+203 (+1.04%)0.03%$0 MNov 16, 2026
69Vanguard Global Advisers, LLC16,4530 (0.00%)0.02%$0 MNov 13, 2026
70Perkins Capital Management Inc16,000New0.02%$0 MNov 2, 2026
71WINTON GROUP Ltd15,200New0.02%$0 MNov 12, 2026
72Two Sigma Investments, LP13,879New0.02%$0 MNov 16, 2026
73Hudson Bay Capital Management LP11,030New0.01%$0 MNov 13, 2026
74Russell Investments Group, Ltd.10,803+1,964 (+22.22%)0.01%$0 MNov 6, 2026
75Persistent Asset Partners Ltd10,444New0.01%$0 MNov 13, 2026
76IMC-Chicago, LLC10,316-4,250 (-29.18%)0.01%$0 MNov 5, 2026
77Canton Hathaway, LLC10,000New0.01%$0 MOct 23, 2026
78Jpmorgan Chase & Co4,097+3,349 (+447.73%)0.01%$0 MNov 12, 2026
79FMR LLC3,451-1,610 (-31.81%)0.00%$0 MNov 10, 2026
80BNP Paribas Financial Markets2,494-146,321 (-98.32%)0.00%$0 MNov 12, 2026
81Royal Bank Of Canada2,449-8,709 (-78.05%)0.00%$0 MNov 16, 2026
82Jones Financial Companies Lllp2,329New0.00%$0 MNov 13, 2026
83Citigroup Inc2,313-306 (-11.68%)0.00%$0 MNov 4, 2026
84Osaic Holdings, Inc.7950 (0.00%)0.00%$0 MNov 12, 2026
85Physician Wealth Advisors, Inc.7750 (0.00%)0.00%$0 MOct 20, 2026
86GAMMA Investing LLC6810 (0.00%)0.00%$0 MOct 8, 2026
87SBI Securities Co., Ltd.453-5 (-1.09%)0.00%$0 MOct 22, 2026
88Wells Fargo & Company/mn1500 (0.00%)0.00%$0 MNov 16, 2026
89Transamerica Financial Advisors, LLC1190 (0.00%)0.00%$0 MNov 12, 2026
90Federation des caisses Desjardins du Quebec1040 (0.00%)0.00%$0 MNov 16, 2026
91PNC Financial Services Group, Inc.94-30 (-24.19%)0.00%$0 MNov 6, 2026
92Robinhood Markets, Inc.64—0.00%$0 MNov 18, 2026
93TD Waterhouse Canada Inc.590 (0.00%)0.00%$0 MOct 16, 2026
94UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC24New0.00%$0 MNov 16, 2026
95IFP Advisors, Inc7-5 (-41.67%)0.00%$0 MOct 16, 2026
96EverSource Wealth Advisors, LLC6-600 (-99.01%)0.00%$0 MNov 4, 2026

Mutual funds holding Neuronetics, Inc.#

28 funds hold shares worth $4 M (about 2.1% of the company). Since their previous reports 4 added shares and 42 sold, selling $4 M net.
Mutual funds holding Neuronetics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.06 M$1 M0.87%<0.01%−34%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.424,323$1 M0.35%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC217,184$0 M0.18%<0.01%−46%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.189,766$0 M0.16%<0.01%−2.9%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC95,205$0 M0.08%0.08%no changeJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors93,494$0 M0.08%<0.01%−0.5%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.87,050$0 M0.07%<0.01%−14%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC69,400$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 1290 VT GAMCO Small Company Value PortfolioEquitable Investment Management Group, LLC75,000$0 M0.06%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC58,666$0 M0.05%<0.01%+6.9%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC45,586$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.35,270$0 M0.03%<0.01%+3.1%May 31, 2026
🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC36,487$0 M0.03%0.03%—Mar 31, 2026
🇺🇸 The Gabelli Small Cap Growth FundGabelli Funds, LLC30,000$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.26,296$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company19,442$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC7,545$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC6,433$0 M<0.01%<0.01%−6.4%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION4,400$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 TETON Westwood Mighty Mites FundTeton Advisors, LLC5,000$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.2,941$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC1,750$0 M<0.01%<0.01%+2.6%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC1,369$0 M<0.01%<0.01%−44%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1,381$0 M<0.01%<0.01%−43%May 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC1,556$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC1,266$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,350$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC145$0 M<0.01%<0.01%−27%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 28 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Neuronetics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$4.9 M
16 purchases, 1 insider
Sold, 12 months
$4.7 M
15 sales, 4 insiders
Net, 12 months
$181 K
open market only
Insiders on file
33
since
$3.6 M-$13.0 M$0Dec 2023: bought $0 (0 trades), sold $87 K (3 trades)Dec 23Jan 2024: bought $0 (0 trades), sold $60 K (2 trades)Feb 2024: bought $0 (0 trades), sold $586 K (12 trades)Jun 2024: bought $103 K (1 trades), sold $0 (0 trades)JunJul 2024: bought $0 (0 trades), sold $92 K (3 trades)Aug 2024: bought $165 K (8 trades), sold $0 (0 trades)Sep 2024: bought $95 K (2 trades), sold $0 (0 trades)SepOct 2024: bought $0 (0 trades), sold $2 K (2 trades)Feb 2025: bought $0 (0 trades), sold $656 K (9 trades)Mar 2025: bought $0 (0 trades), sold $10 K (2 trades)MarMay 2025: bought $0 (0 trades), sold $853 K (2 trades)Aug 2025: bought $0 (0 trades), sold $13.0 M (3 trades)Feb 2026: bought $0 (0 trades), sold $164 K (6 trades)FebMar 2026: bought $3.6 M (8 trades), sold $106 K (4 trades)Apr 2026: bought $309 K (2 trades), sold $0 (0 trades)May 2026: bought $754 K (2 trades), sold $0 (0 trades)MayJul 2026: bought $62 K (1 trades), sold $0 (0 trades)Aug 2026: bought $44 K (1 trades), sold $0 (0 trades)Oct 2026: bought $41 K (1 trades), sold $0 (0 trades)OctNov 2026: bought $80 K (1 trades), sold $4.5 M (5 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Neuronetics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Glenn P. MuirDirectorGrant or award+175,000$1.310$229 K576,816Form 4
filed Sasha CucuzDirectorGrant or awardindirect+370,370$1.350$500 K995,370Form 4
filed Jorey Chernett10% ownerSell-2.19 M$1.150$2.5 M7.33 MForm 4
filed Sasha CucuzDirectorOtherindirect+625,000$1.600$1.0 M625,000Form 4
filed Robert CascellaDirectorGrant or award+128,242$1.500$192 K753,259Form 4
filed Robert CascellaDirectorGrant or award+44,758$1.560$70 K798,017Form 4
filed Jorey Chernett10% ownerSell-706,840$1.430$1.0 M9.51 MForm 4
filed Jorey Chernett10% ownerSell-86,757$1.610$140 K10.22 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Neuronetics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
6.7 M
9.7% of shares · 9.89 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-28.99 reverse split

Trading halts

  • 2025-08-05 15:33 UTC, code LUDP, resumed 15:38 UTC

Fails to deliver

  • : 5,524 shares at $2.08
  • : 1,392 shares at $2.01
  • : 5,865 shares at $2.88
  • : 1,000 shares at $2.80
  • : 1,078 shares at $3.01

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Neuronetics, Inc. scorecard#

Passes 7 of the 22 checks that could be worked out: strongest in growth (4 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 23, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median7.2×Price to book 7.2× against Diagnostics and Research's median of 3.7×.
    • ✓Price to sales below its peers' median1.0×Price to sales 1.0× against Diagnostics and Research's median of 4.5×.
    • ✗Free cash flow yield above 5%-13.1%Free cash flow is -13.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 6
    • ✓Revenue grew in the newest year99.2%Revenue up 99.2% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years31.8%31.8% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median31.8%31.8% a year against Diagnostics and Research's median of 3.6% (64 companies).
    • ✗Earnings per share grew in the newest year-0.59 vs -1.38Diluted EPS -0.59 in fiscal 2025 against -1.38 the year before (report's currency).
    • ✗Net income higher than five years earlier-$39 M-$39 M in fiscal 2025 against -$27 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$39 MNet income -$39 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-21.1%-21.1% against Diagnostics and Research's median of -2.4% (66 companies).
    • ✗Return on equity above 15%-155.7%-155.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-21.1%-21.1% in fiscal 2025 against -53.8% in 2022.
  • Financial health1 of 5
    • ✓Short-term assets cover short-term liabilities2.0×Current ratio 2.02 at the end of fiscal 2025.
    • ✗Debt below equity2.9×Debt to equity 2.94 at the end of fiscal 2025.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-4.1×Operating income -4.1 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-3.11Z-score -3.11 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year107.8%Diluted shares up 107.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Neuronetics, Inc.'s statements, beside the median of Diagnostics and Research.

Neuronetics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-21.1%-2.4%
Net margin-26.2%-3.6%
Return on equity-155.7%-5.4%
Revenue growth, 3 years a year31.8%3.6%
Revenue growth99.2%6.6%
Debt to equity2.94×0.57×

4of 9on the Piotroski tests of financial strength

  • Net loss of $39 million, the 10th loss-making year in a row.
  • Free cash flow was negative: -$21 million.
  • The share count rose 107.8% in the year.
  • Operating income covers the interest bill only -4.1 times.

Neuronetics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Neuronetics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue149757165554963534034
Cost of revenue77212015121215129.66.6
Gross profit72545250443847403128
Research and development6.6139.59.37.99.2148.27.98.2
Selling and marketing47464750383343382822
General and administrative50302526261817148.66.9
Operating expenses104898285716074604437
Operating income−31−35−31−35−28−22−27−20−14−9.3
Interest expense and finance costs8.47.35.44.34.04.53.73.72.81.8
Other non-operating income (expense)0.72.55.82.20.40.31.6−0.60.4−0.1
Income before tax——————−29−24−16−11
Net income including minority interests−39−44−30−37−31−27−29−24−16−11
Minority interests' share of net income−0.1−0.0————————
Net income attributable to shareholders−39−44−30−37−31−27−29−24−16−11
Earnings per share, basic-0.59-1.38-1.05-1.38-1.22-1.46-1.58-2.69-86.34-76.95
Earnings per share, diluted-0.59-1.38-1.05-1.38-1.22-1.46-1.58-2.69-86.34-76.95
Shares, weighted average (basic)66322927251918———
Shares, weighted average (diluted)663229272519188.90.20.1
Balance sheet
Cash and cash equivalents281860709449761052917
Receivables162316147.77.26.65.64.3—
Inventory4.34.28.18.96.63.72.82.42.5—
Other current assets2.96.84.82.23.12.21.81.81.1—
Current assets62589499115658811437—
Property, plant and equipment4.56.22.02.01.20.71.11.41.4—
Right-of-use (leased) assets24272.83.33.93.43.8———
Goodwill2419————————
Other intangible assets1820————————
Total assets1421411161171417910011739—
Accounts payable11114.82.44.33.74.63.82.5—
Debt due within a year———13——11—0—
Current liabilities313120331614281412—
Long-term debt665559233535203030—
Lease liabilities (non-current)19232.33.03.53.12.6———
Total liabilities11510982605653524644—
Retained earnings−459−420−376−346−309−278−250−221−197—
Shareholders' equity2228345785254871−193−177
Minority interests3.94.1————————
Total equity2632345785—————
Total liabilities and equity1421411161171417910011739—
Shares outstanding69562927261919180.2—
Cash-flow statement
Depreciation and amortization3.52.12.01.61.10.91.10.90.60.7
Share-based compensation6.85.67.38.77.94.43.41.70.50.2
Cash from operating activities−20−31−32−31−28−28−30−21−11−8.5
Capital expenditure−0.8−1.5−2.4−3.3−2.4−0.7−0.8−1.0−0.6−0.3
Acquisitions, net of cash acquired—−2.6————————
Cash from investing activities−0.8−2.4−1.36.7−9.8−0.7−0.8−1.0−0.6−0.3
Debt issued105725——41————
Debt repaid—−60−1.2——−39————
Shares issued————81—————
Cash from financing activities36−6.8230.2832.42.497244.9
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Neuronetics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Service(total)$87 M58%
  • Products and Other(total)$62 M42%

Business segments

  • Clinical Services$87 M58%
  • Medical Device$62 M42%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Neuronetics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$4.4 M
Mr. Sullivan
Other top executives, average
$2.2 M
the CEO earned 2× this
$100 invested is now
$20
Neuronetics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mr. Sullivan$4.4 M$2.2 M$2.2 M$20
2024Mr. Sullivan$2.4 M$1.8 M$1.1 M$14
2023Mr. Sullivan$3.0 M−$1.9 M$1.3 M$26

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Neuronetics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Restructuring 1 · Acquisition or sale completed 1 · Directors and officers 13 · Material agreement 9 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 11

Neuronetics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreement8-K
Material agreement8-K/A
Material agreement8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K
RestructuringDirectors and officersMaterial agreement8-K
Directors and officersResults announced8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Directors and officersResults announced8-K
Material agreementResults announced8-K
Directors and officers8-K
Shareholder vote8-K
Directors and officersResults announced8-K
Results announced8-K/A
Directors and officers8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 acquisitions, $39 M paid where reported · 5 private funding rounds before listing

Businesses it acquired

Acquisitions by Neuronetics, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
Greenbrook2024—$39 M—Annual report

Private share sales · funding history

Private share sales of Neuronetics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2017$15 MNo. 5$10 to $50 million22equitySEC
Apr 2015$34 MNo. 4$10 to $50 million23equitySEC
Nov 2014$9 MNo. 3$2 to $10 million23optionsSEC
May 2011$30 MNo. 2$10 to $50 million22equitySEC
Aug 2009$30 MNo. 1$10 to $50 million17equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Neuronetics, Inc.#

$0 spent on lobbying the US Congress and federal agencies in 2025.

Lobbying, 2025
$0
#1,544 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$0

Lobbying firms hired in 2025

CHECKMATE GOVERNMENT RELATIONS

Neuronetics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$0—3
2025$0—1
2024$90 K—3
2023$75 K—2

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Neuronetics Inc.” and “Neuronetics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Layoffs at Neuronetics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
1 notices and filings
People, all years
0
2020–2026
Latest
—
2026-03-31
Neuronetics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026···········—
2024············—
2020············—
Neuronetics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
5% of workforceRestructuring planSEC 8-K“On April 2, 2026, the Company initiated a workforce reduction, which it expects to be completed by mid-year 2026, that will impact up to 5% of its employees.”Filing
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Neuronetics, Inc. compares in Diagnostics and Research

  • Market cap$162 M · higher than 30% of 110
  • Revenue$149 M · higher than 40% of 123
  • Net margin-14.4% · higher than 28% of 112
  • Revenue growth99.2% · higher than 93% of 89
  • Price / sales1.0× · lower than 86% of 85
  • Price / book7.2× · lower than 27% of 84
  • FCF yield-13.1% · higher than 26% of 66

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
Neuronetics, Inc.🇺🇸$162 M—-14.4%+99.2%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 23, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, Wikidata, value.today research, Wikipedia, Wikimedia Commons, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Neuronetics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Neuronetics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Neuronetics, Inc.? Suggest a correction